The Severe Acute Respiratory Syndrome (SARS) causes significant mortality and no effective vaccine is available. Viruses closely related to SARS coronavirus (SARS-CoV) have been found in bats in several parts of the world, making re-emergence of SARS a distinct possibility. We propose to develop a safe inactivated and second-generation vaccine to prevent SARS. We showed that virus deleted in the small envelope (E) protein (rSARS-CoV-Delta E), or in this E protein plus six additional genes (6, 7a, 7b, 8a, 8b, and 9b) accessory for replication were attenuated in hamsters and mice. Among the deleted genes, E gene was the main one responsible for virus attenuation in the animal models tested. Thus, virus with either deleted or mutated E protein serves as a useful platform for the production of a chemically inactivated vaccine, and for the engineering of a live attenuated anti-SARS vaccine. We have shown that SARS-CoV E protein regulates host stress and unfolded protein responses and, consequent immune responses to the virus. We propose the identification and construction of rSARS-CoV including E protein mutants that elicit strong immune responses and are still attenuated.
The specific aims of this project are: (i) The construction of rSARS-CoV viruses with modified E protein mutants eliciting higher immune responses to the virus by maintaining E protein's role in morphogenesis. We hypothesize that preventing the interaction of E protein with host cell proteins involved in stress response signaling will lead to an enhanced immune response. E protein mutant construction will be based on the generation of an rSARS-CoV with a mutator phenotype. (ii) To test rSARSCoV-E* as vaccine candidates in mice using a mouse adapted prototype. We will analyze the immune responses to selected vaccine candidates, and the influence of non-essential group specific genes and of age. (iii) To increase the safety and titer of selected rSARS-CoV-E* vaccine candidates by modification of replicase genes, and to increase vaccine candidate titers using a virus with mutator phenotype.
This proposal describes the development of a novel attenuated vaccine that will protect against SARS as no vaccine is available. The possibility of recurrence exists, since SARS-like CoV are present in bats. Thus, it is important to develop a vaccine that will be safe and immunogenic in order to protect human populations in future outbreaks of this disease.
|Park, Jung-Eun; Li, Kun; Barlan, Arlene et al. (2016) Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism. Proc Natl Acad Sci U S A 113:12262-12267|
|ZuÃ±iga, Sonia; Pascual-Iglesias, Alejandro; Sanchez, Carlos M et al. (2016) Virulence factors in porcine coronaviruses and vaccine design. Virus Res 226:142-151|
|Perlman, Stanley; Vijay, Rahul (2016) Middle East respiratory syndrome vaccines. Int J Infect Dis 47:23-8|
|Meyerholz, David K; Lambertz, Allyn M; McCray Jr, Paul B (2016) Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract: Implications for the Middle East Respiratory Syndrome. Am J Pathol 186:78-86|
|Vijay, Rahul; Perlman, Stanley (2016) Middle East respiratory syndrome and severe acute respiratory syndrome. Curr Opin Virol 16:70-6|
|Fehr, Anthony R; Channappanavar, Rudragouda; Jankevicius, Gytis et al. (2016) The Conserved Coronavirus Macrodomain Promotes Virulence and Suppresses the Innate Immune Response during Severe Acute Respiratory Syndrome Coronavirus Infection. MBio 7:|
|Zhang, Naru; Channappanavar, Rudragouda; Ma, Cuiqing et al. (2016) Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol 13:180-90|
|Luke, Thomas; Wu, Hua; Zhao, Jincun et al. (2016) Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med 8:326ra21|
|Channappanavar, Rudragouda; Fehr, Anthony R; Vijay, Rahul et al. (2016) Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe 19:181-93|
|Alshukairi, Abeer N; Khalid, Imran; Ahmed, Waleed A et al. (2016) Antibody Response and Disease Severity in Healthcare Worker MERS Survivors. Emerg Infect Dis 22:|
Showing the most recent 10 out of 80 publications